Evidence map›Paper›PMID 28513421›Full record

ArticleThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease2017

Clinical and bacteriological characteristics associated with clustering of multidrug-resistant tuberculosis.

J-Y Feng, L G Jarlsberg, K Salcedo, J Rose, M Janes, S-Y G Lin, D H Osmond, K C Jost, M K Soehnlen, J Flood and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Low-Level Rifampin Resistance andJournal of clinical microbiology · 2021
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

J-Y FengCurry International Tuberculosis Center, and Division of Pulmonary and Critical Care Medicine, University of California, San Francisco, Zuckerberg San Francisco General Hospital, San Francisco, California, USA, Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan.
L G JarlsbergCurry International Tuberculosis Center, and Division of Pulmonary and Critical Care Medicine, University of California, San Francisco, Zuckerberg San Francisco General Hospital, San Francisco, California, USA.
K SalcedoDivision of Communicable Disease Control, Center for Infectious Diseases, California Department of Public Health, Richmond, California.
J RoseCurry International Tuberculosis Center, and Division of Pulmonary and Critical Care Medicine, University of California, San Francisco, Zuckerberg San Francisco General Hospital, San Francisco, California, USA.
M JanesCurry International Tuberculosis Center, and Division of Pulmonary and Critical Care Medicine, University of California, San Francisco, Zuckerberg San Francisco General Hospital, San Francisco, California, USA.
S-Y G LinDivision of Communicable Disease Control, Center for Infectious Diseases, California Department of Public Health, Richmond, California.
D H OsmondDepartment of Epidemiology and Biostatistics, University of California, San Francisco, California.
K C JostMycobacteriology/Mycology Group, Texas Department of State Health Services, Austin, Texas.
M K SoehnlenMicrobiology Section, Michigan Department of Health and Human Services, Lansing, Michigan.
J FloodDivision of Communicable Disease Control, Center for Infectious Diseases, California Department of Public Health, Richmond, California.
E A GravissHouston Methodist Research Institute Molecular Tuberculosis Laboratory, Department of Pathology and Genomic Medicine, Houston Methodist Research Institute, Houston, Texas.
E DesmondDivision of Communicable Disease Control, Center for Infectious Diseases, California Department of Public Health, Richmond, California.
P K MoonanDivision of Global HIV and Tuberculosis, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
P NahidCurry International Tuberculosis Center, and Division of Pulmonary and Critical Care Medicine, University of California, San Francisco, Zuckerberg San Francisco General Hospital, San Francisco, California, USA.
P C HopewellCurry International Tuberculosis Center, and Division of Pulmonary and Critical Care Medicine, University of California, San Francisco, Zuckerberg San Francisco General Hospital, San Francisco, California, USA.
M Kato-MaedaCurry International Tuberculosis Center, and Division of Pulmonary and Critical Care Medicine, University of California, San Francisco, Zuckerberg San Francisco General Hospital, San Francisco, California, USA.

Funding

TB Surrogate Markers for Assessing Reponse to Treatment (TB SMART Study)R01AI104589 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI NAHID, PAYAM, SIGAL, GEORGE B · 2013 to 2017
$6.2M
Effect of Drug Resistance on Transmissibility and Pathogenicity of M. tuberculosiR01AI076476 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HOPEWELL, PHILIP C · 2009 to 2013
$3.6M
Intramural CDC HHS CC999999NIAID NIH HHS R01 AI076476NIAID NIH HHS R01 AI104589
6 · The paper itself

Abstract

settingThe impact of the genetic characteristics of Mycobacterium tuberculosis on the clustering of multidrug-resistant tuberculosis (MDR-TB) has not been analyzed together with clinical and demographic characteristics.

objectiveTo determine factors associated with genotypic clustering of MDR-TB in a community-based study.

designWe measured the proportion of clustered cases among MDR-TB patients and determined the impact of clinical and demographic characteristics and that of three M. tuberculosis genetic characteristics: lineage, drug resistance-associated mutations, and rpoA and rpoC compensatory mutations.

resultsOf 174 patients from California and Texas included in the study, the number infected by East-Asian, Euro-American, Indo-Oceanic and East-African-Indian M. tuberculosis lineages were respectively 70 (40.2%), 69 (39.7%), 33 (19.0%) and 2 (1.1%). The most common mutations associated with isoniazid and rifampin resistance were respectively katG S315T and rpoB S531L. Potential compensatory mutations in rpoA and rpoC were found in 35 isolates (20.1%). Hispanic ethnicity (OR 26.50, 95%CI 3.73-386.80), infection with an East-Asian M. tuberculosis lineage (OR 30.00, 95%CI 4.20-462.40) and rpoB mutation S531L (OR 4.03, 95%CI 1.05-23.10) were independent factors associated with genotypic clustering.

conclusionAmong the bacterial factors studied, East-Asian lineage and rpoB S531L mutation were independently associated with genotypic clustering, suggesting that bacterial factors have an impact on the ability of M. tuberculosis to cause secondary cases.

Indexed as

AdultAntitubercular AgentsBacterial ProteinsCaliforniaCluster AnalysisDrug Resistance, Multiple, BacterialFemaleGenotypeHumansIsoniazidMaleMicrobial Sensitivity TestsMiddle AgedMutationMycobacterium tuberculosisRifampinAntitubercular AgentsBacterial ProteinsIsoniazidRifampin

Identifiers

PMID28513421
PMCPMC6643968

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.